<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444743</url>
  </required_header>
  <id_info>
    <org_study_id>MM-093-03-200</org_study_id>
    <secondary_id>IND #100,184</secondary_id>
    <nct_id>NCT00444743</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of MM-093 to Treat Patients With Uveitis</brief_title>
  <official_title>A Phase 2, Double - Blind, Placebo - Controlled, Randomized Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability, pharmacokinetics,&#xD;
      pharmacodynamics, and biologic activity of MM-093 in patients with moderate to severe&#xD;
      uveitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of MM-093, as compared to placebo, when administered as a monotherapy once a week for 24 weeks after discontinuing IMT therapy.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the biological activity of MM-093, as compared to placebo, as defined by the proportion of patients who have a relapse in their uveitis after discontinuing IMT therapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the time to relapse of uveitis after IMT therapy has been discontinued.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the degree of IMT tapering before a recurrence of uveitis occurs.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate visual function as evidenced by visual acuity and by electroretinography.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate sub clinical inflammation as measured by fluorescein angiography.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the formation of anti-MM-093 antibodies after MM-093 administration.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the formation of anti-goat antibodies after MM-093 administration.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-093</intervention_name>
    <description>60 mg, administered subcutaneously, weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years and above&#xD;
&#xD;
          -  Understand, sign, and date the written voluntary informed consent form at the&#xD;
             screening visit prior to any protocol - specific procedures being performed.&#xD;
&#xD;
          -  Have been diagnosed with sarcoid or birdshot uveitis&#xD;
&#xD;
          -  Be able and willing to comply with study visits and procedures per protocol.&#xD;
&#xD;
          -  Women of child bearing potential must use medically acceptable means of birth control&#xD;
             in an effective manner and agree to continue its use during the study and 6 weeks&#xD;
             after the last dose of study drug.&#xD;
&#xD;
          -  Sexually active men must agree to use a medically acceptable form of contraception&#xD;
             during the study and continue for 4 weeks after the last dose of study drug.&#xD;
&#xD;
          -  Able to store patient kit/cooler containing study drug in a refrigerator at home.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant concurrent medical diseases including:&#xD;
&#xD;
               -  Cancer or history of cancer, or lymphoproliferative disorder (other than&#xD;
                  sarcoidosis or successfully resected cutaneous basal or squamous cell carcinoma)&#xD;
                  within 5 years before the screening visit.&#xD;
&#xD;
               -  Any condition for which participation in this study is judged by the physician to&#xD;
                  be detrimental to the patient, such as history of significant or unstable&#xD;
                  cardiac, pulmonary, gastrointestinal, neurological, or psychiatric disease.&#xD;
&#xD;
               -  Significant ongoing infection requiring systemic antibiotic, antifungal,&#xD;
                  antiviral, or ant anti-mycobacterial therapy.&#xD;
&#xD;
          -  Autoimmune or connective tissue disorder other than sarcoid or birdshot uveitis, (e.g.&#xD;
             Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Scleroderma.)&#xD;
&#xD;
          -  Other known active eye diseases or eye infections (bacterial, fungal, or viral) that&#xD;
             may interfere with the evaluation of uveitis.&#xD;
&#xD;
          -  Grade 2 or above liver function abnormality&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Any previous history of immunodeficiency syndromes or infection with human&#xD;
             immunodeficiency virus (HIV), or a history of hepatitis C or chronic hepatitis B.&#xD;
&#xD;
          -  Live viral or bacterial vaccinations within 3 months prior to screening, or planning&#xD;
             to receive such vaccinations during the trial, or up to 3 months after the last&#xD;
             injection of MM-093.&#xD;
&#xD;
          -  Pregnant or breastfeeding women or women planning to become pregnant during the study&#xD;
             or within 4 weeks after the last dose of the study drug.&#xD;
&#xD;
          -  Scheduled elective surgery during study participation&#xD;
&#xD;
          -  Participated in any previous clinical trials using MM-093 or have any prior exposure&#xD;
             to MM-093.&#xD;
&#xD;
          -  History of severe hypersensitivity to goat, sheep, or cow milk products derived from&#xD;
             goat, sheep or cow milk (patients who are lactose intolerant are not excluded.)&#xD;
&#xD;
          -  Any other acute or clinically important condition that the investigator feels would&#xD;
             jeopardize the integrity of the study (e.g. a CTCAE grade 2 or above clinical finding&#xD;
             or laboratory result.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Stephen Foster</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye Research and Surgery Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MERSI</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>December 16, 2008</last_update_submitted>
  <last_update_submitted_qc>December 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2008</last_update_posted>
  <responsible_party>
    <organization>Merrimack Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

